Gilead's Remdesivir Shows Fair Improvement In Moderate COVID-19 Patients
Gilead Sciences Inc on Monday reported that its antiviral drug remdesivir provided a modest benefit in patients with moderate COVID-19 given a five-day course of the treatment, while those who...
No comments:
Post a Comment